Crossmark

Caplacizumab in acquired thrombotic thrombocytopenic thrombocytopenic purpura: dose adjustment based on von Willebrand factor level

Crossref DOI link: https://doi.org/10.1016/j.medcle.2023.04.028

Published Print: 2023-09

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Albanell-Fernández, Marta

Monge-Escartín, Inés

Cid, Joan
License Information

Text and Data Mining valid from 2023-09-01

stm-asf valid from 2023-09-01

stm-asf valid from 2023-09-01

stm-asf valid from 2023-09-01

stm-asf valid from 2023-09-01

stm-asf valid from 2023-09-01
More Information

This article is maintained by: Elsevier

Article Title: Caplacizumab in acquired thrombotic thrombocytopenic thrombocytopenic purpura: dose adjustment based on von Willebrand factor level

Journal Title: Medicina Clínica (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.medcle.2023.04.028

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.medcli.2023.04.017

Content Type: simple-article

Copyright: © 2023 Elsevier España, S.L.U. All rights reserved.